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A Rare Case of Cytomegalovirus Retinitis with Subsequent Immune Reconstitution 
Uveitis 
 
Tracy Doll, O.D., F.A.A.O. 
Pacific University College of Optometry 
 
Abstract 
 
A routine eye exam on a young male patient finds asymptomatic retinal lesions 
suggestive of retinal necrosis.  Confirmatory medical laboratory tests reveal a diagnosis 
of cytomegalovirus retinitis in the setting of an HIV infection. Subsequent treatment 
leads to immune reconstitution uveitis. 
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Introduction 
 
Cytomegalovirus retinitis (CMVR) is the most common cause of blindness in patients 
diagnosed with AIDS. With the advent of modern HIV treatment, the CMVR rates have 
been dramatically reduced, but still persist.  One in five patients infected with HIV are 
unaware they have contracted the virus.  I report here on one such patient: an 
asymptomatic patient with CMVR in the setting of a previously undiagnosed HIV 
infection, with subsequent immune reconstitution uveitis. I will also discuss current 
treatment, prognosis and complications  
 
Case Presentation 
 
  
Subjective 
 
A 25 year old Hispanic male, presented with a chief concern of itchy eyes for the 
duration of six months. He had no other visual complaints.  His ocular history was 
unremarkable and this was his first eye examination. 
 
His systemic history is significant only for nail fungus for which he was on an oral anti-
fungal medication of unknown name.  
 
Objective 
 
Uncorrected incoming visual acuity was measured at 20/25 OD and 20/50 OS 
Best corrected visual acuity was 20/20 OD and 20/25- OS.  
 
Confrontational visual fields, extra-ocular motilities and pupils were all found to be 
within normal limits. 
 
External and biomicroscopy examination revealed bilateral mildly inflamed pingueculae, 
worse on the left eye.   The anterior segments OU at that time were quiet. No 
inflammatory cells in the aqueous were present. 
 
Intraocular pressures, as measured with Goldmann applanation tonometry were 8mmHg 
OD and OS. 
 
Posterior examination OD was remarkable for one isolated dot blot heme in the posterior 
pole just off the optic nerve inferior nasal. The nerve itself was healthy with moderate 
cup to disc ratio. 
 
Posterior examination OS showed a diffuse 2+ vitritis, but views of the retina were still 
obtainable. The posterior pole was remarkable for scattered dot-blot hemorrhages.  At the 
end of the vascular arcades extending into the peripheral retina, particularly superiorly, 
extensive patches of exudates, hemorrhaging and vascular shealthing adjacent to areas of 
white, necrotic retina were detected.   The retina appeared to be attached 360 degrees.  
The optic nerve head was healthy and the macula was attached, though it was difficult to 
ascertain whether or not macular edema was present due to vitritis. 
 
Blood pressure in office was measured at 116/72mmHg.  Non-fasting blood glucose was 
measured at 120mg/dL.  Photo-documentation of mid-peripheral lesions were taken at 
that time, though hazy as taken through 2+ vitreal cells.  See Figures 1 and 2 below. 
 
FIGURE 1: Posterior Pole View of Right and Left Eye 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: Mid-peripheral Lesion Left Eye 
  
 
Assessment and Plan: 
When questioned, the patient denied any pain or noticeable loss of vision out of the left 
eye. An immediate phone call was placed to facilitate a retinal specialist referral with a 
large optometric group. The patient was triaged to general ophthalmology for evaluation 
the next morning.   
 
At the general ophthalmology visit, a there was a new finding of keratic precipitates on 
the corneal endothelium with a diffuse dendritic appearance on the left eye that had not 
been present the day before.  The visual acuity in the left eye had dropped to 20/70 
unaided. The retinal findings remained unchanged.  Macular edema was confirmed OS 
with the use of OCT (Ocular Coherence Tomography), with central macular thickness of 
302µm (Figure 3). The patient was referred to retinal specialty immediately. 
 
  
 
Blood work and serology were ordered and the Table 1 shows the results:  
 
Table 1: Medical Laboratory Testing Results 
Lab Test Result 
CBC with differential low RBC, hemocrit and hemoglobin as 
well as mildly elevated levels on 
mononucleocytes 
Chemistry calcium 8.5 (nl 8.6-10.3) 
total protein 9.9 (nl 6-8.3)  
aldt sgpt 53 (nl 10-35) 
RPR (Rapid Plasma Reagin) Non-reactive 
ACE (Angiotension Converting Enzyme) WNL 
Lyme Screen  Positive 
Toxoplasma IgG- 12 (High), IgM (negative) 
HIV Pending 
 
Retinal specialty admitted the patient to a hospital for three days, where an intravenous 
Acyclovir regimen was started.  A vitreal tap for further laboratory testing was performed 
and an injection of foscarnet was also performed. Aqueous and vitreal fluid were sent out 
for viral PCR (polymerase chain reaction) testing.   
 
Following his hospital stay, posterior segment findings were relatively unchanged, but 
anterior chamber inflammation had subsided and visual acuity OS was improved to 
20/30.  The diagnosis of Acute Retinal Necrosis (ARN) was given, with suspect CMV-
like lesions.  The patient was to continue intravenous Acyclovir therapy. HIV test results 
had not yet returned. 
 
The patient returned for an appointment a week later when more lab results had returned. 
These lab results can be seen in Table 2. 
 
Table 2: Viral Laboratory Test Results 
Lab Test  Result 
Viral PCR CMV DNA PCR positive 
HSV /VZV negative 
HIV Blood Test Positive 
CD-4/ T-Cell Count 68 cell/µL 
 
The patient was confirmed to be infected with cytomegalovirus (CMV) in the setting of 
an HIV infection. The patient was to have an intravitreal injection of ganciclovir.  His 
acyclovir intravenous treatments were stopped and oral Valcyte (vancyclovir) 900mg 
TID was prescribed for 3 weeks then one pill daily. 
 
One week later the patient returned to retinal specialty with some improvement seen in 
the retina. Areas of whiting were less with less vitritis and improved vascular sheathing. 
He was set to continue with ganciclovir injections and oral Valcyte. 
 
Ten days later, the leading edge of the retinal lesions were becoming pigmented and the 
vitritis was improving. Retinal specialty gave its consent for the patient to begin HAART 
treatment when infectious disease specialty deemed appropriate. No more injections of 
ganciclovir were deemed necessary.  The patient was to be watched carefully in the 
following weeks for immune-constitution uveitis. 
 
About one week later, the CMV retinitis was deemed completely resolved while on the 
HAART and Valcyte treatments. 
  
Unfortunately, about a week later, the patient returned to the retinal specialist with 
concerns of eye pain. Possible mild reconstitution uveitis was detected OS, but no active 
CMVR.  The patient’s CD4 count had risen to 154 cell/ µl, with a viral load of 6400 
copies/ml of plasma. 
 
From that point on, immune reconstitution uveitis with cystoid macular edema has 
plagued the patient (See Figure 3).  
 
FIGURE 3: OCT of Cystoid Macular Edema Secondary to Immune Reconstitution 
Uveitis  
 
 
 
 He was moved from retinal specialty to uveitis and inflammatory ocular disease 
specialty.  His visual acuity has plummeted to counting fingers at 3feet with eccentric 
fixation. The patient continues to be monitored at regular intervals by ophthalmology and 
infectious disease specialties.  
 
Pertinent to this case, is the in-depth infectious disease medical history. The patient 
reported to this specialist of having a sexual history with over 30 different women within 
the five years prior to his HIV/AIDS diagnosis.  
 
 
A flow-chart of the patient’s treatment regimen can be seen below in Table 3. 
 
 
Table 3: Summary of Patient Diagnoses and Treatments 
Date Diagnosis Treatment 
Initial 
Detection 
Initial detection of vitritis and retinal 
lesions - suspect Acute Retinal 
Necrosis (ARN) 
• Referral to Intermediate Site 
for General Ophthalmology  
Next Day General ophthalmology detects mild 
macular edema, suspects ARN  
• Referral to Retinal Specialty 
• Blood work/ serology order  
Day 2 Retinal Specialist confirms ARN with 
suspect CMV lesions 
• Admitted to hospital 
• IV Acyclovir regimen 
•  A vitreal tap/ injection of 
foscarnet 
Day 5 ARN diagnosed with suspect CMV 
lesions 
• In-patient at Hospital 
• Aqueous and vitreal fluid 
were sent out for viral PCR 
• Intravenous Acyclovir 
regimen 
One 
Week 
ARN diagnosed with suspect CMV 
lesions  
• Auto- fluorescent 
photography 
• Intravenous Acyclovir 
regimen 
One 
Week + 
One Day 
Cytomegalovirus retinitis (CMVR) in 
the setting of an HIV infection 
diagnosed based on lab results 
• Intravitreal injection of 
ganciclovir 
• Acyclovir IV treatments 
stopped 
• Oral Valcyte 900mg TID for 
3 weeks then one pill daily 
Two 
Weeks 
 
Cytomegalovirus  Retinitis (CMVR) 
in the setting of an HIV infection  
• Intravitreal injection of 
ganciclovir every other day 
for a total of 3 more 
injections 
• Oral Valcyte 900mg TID  
Week 3.5 Cytomegalovirus Retinitis (CMVR) 
in the setting of an HIV infection 
improving/ almost resolved 
• OK to start HAART 
• Oral Valcyte 900mg TID  
 
Week 4.5  Cytomegalovirus Retinitis (CMVR) 
in the setting of an HIV infection 
resolved 
• HAART 
• Oral Valcyte 900mg qd 
Week 6 Mild immune reconstitution uveitis 
Quiescent CMVR 
• HAART 
• Oral Valcyte 
4 month, 
3 weeks 
Immune reconstitution Uveitis (IRU) 
Cystoid Macular edema (CME) 
Quiescent CMVR 
• HAART 
• Oral Valcyte 900mg qd 
• Pred 60 mg daily (along with 
azithro 1200 mg once weekly 
per HIV MD) 
 
5 months Immune reconstitution Uveitis (IRU) 
Rapid improvement of CME 
 
• HAART 
• Oral Valcyte 900mg qd 
• Periocular Kenalog injections 
• Oral Pred  
6 months Resolution of CME, with little 
subjective VA improvement 
• HAART 
• Oral Valcyte 
• Oral Pred tapered 
8 months CME • HAART 
• Oral Valcyte 
• Periocular Kenalog injection 
1 year 
 
Resolution of CME, with little 
subjective VA improvement 
• HAART 
1.5 Year Resolution of CME, with little 
subjective VA improvement, 
Mild IRU 
• HAART 
• Consider Glaucoma work-up 
• Recommend discontinuation 
of Valcyte 
 
 
 
 
 
 
Discussion 
 
Background  
 
Some demographic groups are at higher risk for contracting HIV.  The fastest growing 
minority in the United States at this time is the Hispanic/ Latino community (5).  The 
patient above belongs to this demographic and so it will be discussed briefly here. 
Although the Hispanic subset makes up about 16% of the current US population, they 
made up a disproportionate 21% of all new HIV diagnoses and accounted for 19% of all 
people living with HIV in the US in 2009 (6). Since the beginning of the AIDS epidemic, 
an estimated 96,200 Hispanic/Latino persons have died from complications due to HIV(6).  
The populations groups most at risk for contracting HIV, in descending order, are: 
Caucasian, Black and then Hispanic Men who have sex with men (MSM). Heterosexual 
men and women also contract HIV infection at high rates.  Table 4 from the CDC shows 
the most at-risk populations (6). 
 
Table 4: Estimated New HIV Infections in the United States, 2010, for the Most Affected 
Subpopulations (6) 
 
 
Source:http://www.cdc.gov/hiv/statistics/basics/ataglance.html 
 
 
The cytomegalovirus (CMV) is a member of the herpes virus family. Normally a healthy 
immune system is able to keep CMV at bay after initial exposure. However, in patients 
with compromised immune systems CMV can flourish. Thus, patients who commonly 
contract CMV are those with the Human Immune Deficiency Virus (HIV). A retinitis 
associated with the CMV infection, Cytomegalovirus Retinitis (CMVR) generally occurs 
with CD4 T-Cell counts lower than 50 cells/ µl. The mean CD4 count at the time of 
diagnosis is 17cells/ µL(1). CMVR was considered a rare condition prior to the 1980s, 
when the AIDS epidemic first began.   The advent of modern HIV treatment (HAART) in 
the 1990s has dramatically reduced the incidence of the condition from around 40% in 
those infected with HIV to 22% (2).  Still, CMVR is the main cause of blindness in HIV 
infected individuals with complications in the eye affecting about 80% of all patients 
infected with both HIV and CMV(2).   The rate of CMVR infection in HIV patients with 
CD4 count less than 50 cells/ µL is currently reported to occur in 0.20/ person-year 
(PY)(1). Recall that a person-year is a “statistical measure representing one person at risk 
of development of a disease during a period of 1 year (3).” A patient with AIDS is 
estimated to have a 20-40% chance of developing CMVR in a lifetime (1,2).  
. 
 
HAART has dramatically reduced the impact of HIV related morbidity and mortality. 
Still, there are 1.1 million people living with HIV in the United States.  In 2011, an 
estimated 49,273 people were diagnosed with HIV infection (4). What is concerning is 
that almost 1 in 5 patients have no idea that they are infected (4).  
 
 
Presentation of CMVR 
 
A patient presenting with CMVR may have few to no symptoms, as was the case with the 
patient discussed and 15% of all diagnosed patients.  If the location of the retinitis is 
largely peripheral, a patient may not know they are infected or present with floaters, 
flashes, scintiallating scotomas or reduced peripheral visual field. If the retinitis is in the 
posterior pole, the patient may be far more symptomatic of decreased vision or scotomas.  
It should be noted that pain and redness of the anterior segment are rare without co-
infection (1,2). 
 
Cytomegalovirus can be unilateral or bilateral. One retrospective study of 222 cases of 
CMVR showed 92 patients to have bilateral disease, while 130 had unilateral disease (7).  
Prompt systemic treatment of unilateral cases has been associated with decreasing the 
rate of the condition spreading to involve the contralateral eye (7). 
 
CMV creates lesions of full-thickness chorioretinal whitening adjacent to hemorrhages 
(see Figure 2). When these lesions are located anatomically from the edge of the posterior 
pole into the region of votex ampula/veins (equator), this is called Zone 2. If located in 
the periphery, anterior to the equator (Zone 3), these lesions can be oriented 
circumferentially and are more granular in appearance. Retinal vasculitis, seen as white” 
frosting” of retinal blood vessels is common adjacent to the lesions.  As the CMV 
progresses (often unnoticed), it leaves in its wake a path of infiltrated atrophic retinal 
pigmented epithelium (RPE) and chorioretinal scarring which appears neighboring the 
white-grey active lesions. CMVR is thought to move through the retina at about 24 µm 
per day if left untreated (1).  Progression in clinical trials is defined  as “movement of a 
lesion border at least 750 µm along a front that is 750 µm or more in length or the 
development of a new CMV lesion in the affected or fellow eye as detected by serial 
fundus photography (2).  
 
Rhegmatagenous retinal detachment might be a secondary finding.  Multiple breaks due 
to attached vitreous at the edge of necrotic tissue are to blame. A retinal detachment most 
often occurs within 3 to 6 months of CMVR diagnosis. With current HIV treatment 
(HAART) retinal detachments generally occur only in patients with more than 25% of the 
retina involved (1,2). 
 If the infection infringes into the posterior pole (Zone 1), large cotton wool spots with or 
without hemorrhage at the macula or papillitis can occur.  Cataracts are also a common 
secondary finding (1,2).   
 
Visual impairment and blindness from CMVR is usually attributable to edema of macula 
and nerve, retinal detachment and cataract formation.  
 
Uveitis and vitiris specifically in response to CMV is considered rare. When a marked 
uveitis or vitritis is detected, it is usually secondary to a concurrent infection such as 
toxoplasmosis, syphilis, varicella zoster or simplex, or lymphoma (1,2).  Interesting to note 
is that the patient above had an Immunoglobulin G response that measured high for 
Toxoplasma. He also had a positive Lyme titer. His vitritis is easily seen in Figure 1. 
 
 
Diagnosis of CMVR 
 
The diagnosis of CMVR is made based on clinical presentation confirmed with medical 
laboratory testing.    As CMVR is rare without co-infection of HIV, (congential 
transmission as well as other immune-compromising disorders can leave a patient open to 
contracting CMVR (1)), HIV testing is standard protocol.  Blood testing can be done to 
identify infection for HIV and samples of vitreal fluid can be obtained to identify CMV 
as the culprit of the retinitis. 
 
The Enzyme Linked Immunosorbent Assay (ELISA) is a blood serum testing method, not 
a specific test for one kind of disease. Blood is exposed to antibodies for specific diseases 
in the ELISA.  If a disease is present, antibodies laced with florescent markers will “stick 
to” the disease antigen in the serum, indicating an immune response.
 
The main use for 
ELISA is as a screener for HIV(8). 
 
The Western Blot (WB), like the ELISA is a laboratory testing method, not a specific 
disease test. The WB testing separates the blood sample proteins out and then exposes 
these proteins to specific disease antigens, leading to the detection of a disease agent (8). 
The WB’s main use is to confirm HIV after the ELISA screener.  It is the confirmatory 
blood test (8). 
 
HIV confirmation can go hand-in-hand with hematological studies.  HIV targets the 
body’s lymphocytes known as “killer T-cells.” These cells are crucial in the immune 
response. The receptors on the T-Cells that bind HIV are known as CD4 receptors.  
Normal CD4 or T-Cell counts will range from 500 cells/ mm3 to 1,000 cells/ mm3 (You 
should note that in the literature, CD4 count units can be either in mm3 or in µL.  One 
mm3 is equivalent to one µL.)  HIV will lower this number.  AIDS is diagnosed when the 
CD4 count is lower than 200 cell/ µL (9,10). 
 
Along with measuring lowered CD4 counts, the amount of virus in a sample can indicate 
the level of disease.  For this reason, viral loads are often reported alongside CD4 counts. 
A viral load is considered “undetectable” at fewer than 40-75 copies/ mL.  A newly 
diagnosed patient may have millions of viral fragments (copies) that are detected.  
Usually the viral load is looked at over time to watch for trends of increase or decrease.  
An exact viral load number is not diagnostic of AIDS as with the CD4 count.  A higher 
viral load would increase the chance of a lower T-Cell count (11). 
 
The polymerase chain reaction test is used to identify specific viral agents, including 
CMV, the herpes simplex virus (HSV), and varicella zoster virus (VZV).  PCR is a 
process where small sequences of DNA within a sample are replicated repeatedly.  The 
DNA of the sample is compared to known DNA sequences of suspected viral entities.  In 
this manner CMV can be confirmed (12). 
 
 
 
 
Treatment of CMVR 
 
  
Current treatment for CMVR is initiated as a combination of oral and intravitreal 
injection/ ocular implanted antiviral agents. Treatment is divided into 2 phases: induction/ 
anti-CMV and maintenance/ anti-HIV therapy. 
 
Oral Valcyte (Valganciclovir) is often the first step in induction therapy.  Valcyte has 
excellent bioavailability and has been shown to be as effective as intravenous ganciclovir 
for initiation of CMVR therapy. Intravitreal or ocular implanted ganciclovir is then added 
in patients with Zone 1 involvement or in patients at risk for vision loss.  Implanted 
ganciclovir can also be effective when oral treatment with ganciclovir is not efficacious 
or if the CMV is found to be resistant to oral ganciclovir. There are some strains of CMV 
that have become resistant to the classic treatment of ganciclovir and an older medication, 
foscarnet (1). 
 
If CMVR progresses or reoccurs before the immune system can be reconstituted on 
systemic anti-HIV therapy (HAART), then implanted ganciclovir (Vitrisert) is 
recommended. This implant is also suggested in the cases where HAART is not an option 
for a patient due to poor compliance or response. The implant will last around 5-8 months 
and can be replaced every 7-8 months as needed.  The implant has proven to predispose 
patients to the development of CMVR in the contralateral eye and raises the rates of 
visceral disease and mortality when this treatment is used alone (1).  To insure systemic 
treatment of CMV, oral ganciclovir or valcyte is then used in conjunction. 
 
There is a new intra-vitreal medication potentially coming down the pipelines, although it 
is still in animal trials at this time. Hexadecyloxypropyl-cyclic cidofovir, is a long lasting 
prodrug of cidofovir. This might provide an alternative for those patients who’s CMV 
proves resistant to classic treatments (1).  
 
As was already mentioned, the advent of the modern HIV/AIDS treatment known as 
HAART (Highly Active Antiretroviral Therapy) has dramatically reduced the incidence 
of CMVR. In fact the majority of new cases of CMVR are now occurring in patients who 
cannot be treated with or do not respond to HAART. Once CMV is deemed no longer 
active through use of anti-CMV agents, the maintenance phase of treatment is initiated 
with the use of HAART (1). 
 
HAART is defined as treatment with at least three active antiretroviral medications 
(ARV’s), typically two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) 
with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) 
or integrase inhibitor. The medications listed in Table 5 are aimed at stopping HIV 
replication in the body (13). 
 
Table 5: HAART Therapy Components(14) 
HAART Medication Category Common Medications Names 
Nucleoside/nucleotide reverse transcriptase 
inhibitors 
tenofovir, emtricitabine, abacavir  
Non-Nucleoside/ reverse transcriptase 
inhibitors (NNRTs) 
efavirenz, nevirapine, etravirine  
Protease Inhibitors (PIs) atazanavir, ritonavir, darunavir 
Fusion and Entry Inhibitors enfuvirtide and maraviroc  
Integrase Inhibitors raltegravir 
 
Typical combinations of HAART include (14): 
 Efavirenz + tenofovir + emtricitabine 
Ritonavir-boosted atazanavir + tenofovir + emtricitabine 
Ritonavir-boosted darunavir + tenofovir + emtricitabine 
Raltegravir + tenofovir + emtricitabine 
 
HAART was originally a combination of zidovudine (AZT) in 1985, didanosine in 1991 
and zalcitabine in 1992. These drugs became the foundation for new generation of 
HAART medications(1,12,13). 
 
Valcyte is also used past induction into the maintenance phase of CMVR treatment.  
Once CMVR is deemed no longer active, oral Valcyte or anti-CMV treatment is 
generally continued for 3-6 months alongside systemic HAART to insure that the 
immune system is reconstituted. If a patient is already on HAART, anti-CMV therapy 
can be discontinued only once the patient has a CD4 count consistently above 100 cells/ 
µl at two consecutive times, three months apart. The CMVR should also be inactive for 
more than four months. These patients are watched carefully, on average at about three 
month intervals to lookout for any reoccurrence.  There is no CD4 count that is 
considered protective at this time (1). 
 
Although CMVR rates and severity have been improved with the use of HAART, the use 
of HAART is not always without consequence in the eye.  Immune reconstitution uveitis 
(IRU) can occur when the body’s immune system recovers partially with the use of 
HAART. 
“The AIDS Clinical Trial Group defined IRU as a 'decrease in vision and at least 
two of the following signs in the absence of active CMVR: presence of >2+ 
inflammatory cells in vitreous by slit lamp examination, cystoid macular edema 
(CME) or epiretinal membrane formation in patients receiving potent 
antiretroviral therapy with evidence of immune reconstitution.”  
Or 
“NIH sponsored Studies of the Ocular Complications of AIDS is 'the occurrence 
of intermediate uveitis in patients with CMVR who have evidence of immune 
reconstitution, as shown by a rise in CD4 T-cell counts after the initiation of 
HAART (1).” 
 
The mechanism of how IRU occurs is not proven.  The theory is that CMV antigens still 
exist in the eye, even when the infection is no longer active. The reconstituted immune 
system then attempts to fight these antigens. CMVR damage to the eye breaks down the 
blood-brain barrier and allows for inflammatory cells to more easily enter the eye.  One 
study demonstrated that patients with partial versus full immune recovery tend to 
experience IRU more often. Other risk factors for IRU include more extensive retinal 
involvement in cases with more than 30% of the retina (versus only 18%) involved (1).  
The use of cidofovir for treatment is also associated with a higher incidence of IRU. 
Secondary complications from IRU (other than uveitis and vitritis) include optic nerve 
and macular edema (see figure 4 above), and epiretinal membrane/vitreomacular traction 
development.  Retinal neovascularization can also occur.  
 
The best treatment for IRU (and the treatment that was provided to the patient above) is 
systemic and ocular steroids with about a 50% success rate.  Small sample case studies 
have also shown that steroid implants along with CMV therapy (valacicylovir/ 
gancicyclovir) can also be effective, but the subjects for this study had CD4 counts all 
three times the minimum of 100cell/mm3, the level needed for immune reconstitution (1). 
There is also evidence that delaying HAART therapy until the CMVR is no longer active 
can decrease the incidence of IRU.  However the delay of HAART initiation can leave a 
patient open to other opportunistic infections in the body (1).  In the patient above, the 
initiation of HAART therapy was deferred until the CMVR showed improvement. 
.  
 
 
Differential Diagnosis 
 
CMVR is not the only condition that can lead to necrosis of the retina in HIV patients. 
Two other conditions, Acute Retinal Necrosis (ARN) and Peripheral Outer Retinal 
Necrosis (PORN) can also lead to devastating visual outcomes.  It is important to be able 
to differentiate their presentation from that of CMVR.  
 
ARN: 
The atypical presentation of vitiris and uveitis in the case patient above made Acute 
Retinal Necrosis (ARN) the primary differential diagnosis for CMVR.   Even in patients 
without active iritis or vitritis, ARN is still rises to the top of the list for differential 
diagnoses.  
 
Acute retinal necrosis, (ARN) is a rare condition, with predilection for males. It has been 
documented in patients aged 4 though 89 years of age, with the majority of patients 
between the ages of 20-50 years of age. ARN or BARN (bilateral acute retinal necrosis) 
has been associated with herpes simplex (HSV) and varicella zoster (HZV) viruses and in 
immuno-compromised patients with HIV.  It is interesting to note is that AIDS patients 
with higher CD4 counts (>50cell/µL) can develop ARN as well as those with lower CD4 
counts (2,15). 
 
The hallmark features of ARN include significant intraocular inflammation including 
panuveitis, vitritis, vaso-occlusive angiitis of both the retinal and choroidal vessels, and 
necrotizing retinitis.  This inflammation primarily affects the peripheral retina.  If 
untreated, the condition can progress to a rhegmatogenous retinal detachment in the final 
stages (2,15). 
 
The condition can progress rapidly. A patient will commonly first present with a mild 
reduction in vision and mild to moderate peri-orbital pain.  A red eye is often present.  
Due to the predilection of ARN for the peripheral retina in early stages, rarely does ARN 
first present with dramatic central vision loss.  If central vision loss is the primary 
concern, retinal artery occlusion or retinal detachment is usually the culprit.  In the early 
stages ARN can be asymptomatic (2,15).  
 
External examination can reveal variable degrees of acute inflammation.  Episcleritis or 
scleritis can yield a red eye.  A mild to moderate anterior chamber reaction with or 
without keratic precipitates may be present. If present, the KPs can be fine or 
granulomatous.  If the patient has concurrent HIV and HSV infection, stromal or 
dendritic keratitis has been documented to occur (2,15).   
 
 
Posterior segment findings are similar to CMVR.  ARN begins with a diffuse vasculitis 
of both arteries and veins in the retina. This manifests by a distinct sheathing of the larger 
caliber vessels.  Peripheral retinal tissue subsequently (or concurrently) begins to 
necrotize and form full-thickness white patchy lesions. These lesions are known as 
“thumb-print lesions.” Over the span of a couple of days to weeks theses lesions can go 
on to coalesce involving anywhere from one half of a clock hour to the entire peripheral 
retina (2). As the infection progresses towards the posterior pole, perivascular 
hemorrhages, macular edema, retinal artery occlusions and optic disc swelling can occur 
(2).  Many times with ARN, the posterior segment signs may be more difficult to 
visualize, due to a concurrent vitritis.   Debris from the necrotizing retina and 
inflammatory cells can lead to fibrovascular traction and subsequent retinal detachment 
late in the course of ARN syndrome (2,15).  
 
Without treatment, ARN will “burn-out” within 6-12 weeks, leaving behind full-
thickness atrophic, scarred retina and possible retinal breaks at the interface between 
healthy and atrophic retina. Rhegmatagenous retinal detachments can subsequently occur 
during the recovery stage of ARN in 50-70% of patients who go untreated.  Tractional 
detachments can also occur commonly occur as a result of the corresponding vitritis (2,15).   
Current treatments are aimed at the viruses associated with ARN:  HSV, VZV and HIV.   
 
 
PORN 
 
Peripheral Outer Necrosis (PORN) is also a good differential for CMVR.  Like CMVR, 
PORN is also a necrotizing retinitis that commonly affects HIV/AIDS infected 
individuals.  Like ARN, it has been associated with the herpes virus family, particularly 
the varicella zoster virus (HZV).  PORN has also been linked to other viral etiologies 
including: CMV, HSV and the Epstein Barr.   Prior to HAART treatment, PORN came in 
second to CMVR as the cause for blindness in HIV infected individuals (1). 
The progression of PORN is very fast and runs its course within day to weeks. Almost 
70% of cases are bilateral. PORN is linked to patients with almost no immune response 
(CD4< 50 cells/µl). For this reason, it is rarely associated with anterior segment 
inflammation or vitritis. Unlike ARN and CMVR, PORN often begins with cherry-red 
macular lesions in 65% of patients (1,2).  The condition can first appear in the periphery 
and then move toward the macula as well. The initial lesions are often yellowish in color 
with minimal hemorrhaging. Vascular sheathing can also be seen adjacent to lesions or 
the veins can be completely spared (perivenular clearing). As the condition progresses, 
the optic nerve may become edematous and hyperemic. The retina in later stages has a 
“cracked-mud” appearance as retina becomes scarred. Rhegmatagenous retinal 
detachment occurs in 70% of PORN patients, even with treatment (1,2).  The tractional 
detachments that are common in ARN, do not happen with PORN due to lack of vitritis. 
Symptoms are similar to other necrotizing retinal conditions including: photopsia, 
floaters, scotomas and visual acuity changes. 
 
Current treatments are aimed at the underlying associated virus (usually HZV).  Lifelong 
treatment is usually required to keep patients from multiple occurrences.  
 
Table 6 (below) shows common finding that can help differentiate CMVR, ARN and 
PORN   
TABLE 6: Comparison of CMVR, ARN and PORN 
 CMVR ARN PORN 
Most 
Common 
Underlying 
Infection 
CMV HSV  and HZV HZV 
Immune 
Status 
Usually <50 cells/µL Greater or lower than 50 
cells/µL 
Usually <50 cells/µL 
Appearance White-grey adjacent 
to hemorrhages and 
Thumb-print lesions, 
white-grey, hard to 
Yellow-Spots, clearing 
around veins 
exudates/ granular define edges 
Location of 
Lesions 
Anywhere Peripheral inward Inward Peripheral 
Associated 
Inflamm 
Rare Common: uveitis or 
vitritis 
Rare 
Associated 
Retinal 
Detachment 
Rhegmatagenous Rhegmatagenous or 
Tractional 
Rhegmatagenous   
Bilaterally Either Unilateral Bilateral 
Progression 24 µm per day 6-12 weeks Fast: Days to Weeks 
 
Other infectious conditions that can be associated with vitritis include syphilis, 
toxoplasmosis and tuberculosis. These conditions may also have associated retinitis with 
lesions. In HIV infected individuals it is not uncommon for other infections to be 
comorbid with CMV.  For this reason, medical laboratory tests are run to rule out other 
infections. Table 7 below (16) lists medical laboratory tests ordered alongside HIV/CMVR 
testing.  It is interesting to note that in the case presentation above, the patient did test 
show higher levels of IgG, indicating exposure to toxoplasmosis.  
  
TABLE 7- Infectious Disease and Medical Laboratory Tests 
Infectious 
Disease 
Medical Laboratory Test Interpretation 
Toxoplasma IgG, IgM  IgG indicates infection for 
likely >1 year, IgM <1 year 
 
Syphilis VDRL (Venereal Disease Research 
Laboratory), 
RPR (Rapid Plasma Reagin), 
FTA-ABS (Fluorescent 
Treponemal Antibody Absorption 
Test) 
VDRL and RPR are screening 
tests, while FTA-ABS is 
confirmatory 
Tuberculosis PPD (Purified Protein derivative 
skin test) 
Indicates exposure.  >5mm is 
considered a (+) test on an HIV 
patient 
Sarcoidosis ACE (Angiotensin Converting 
Enzyme)  
ACE is 75% sensitive for 
sarcoid and; it is 95% specific if 
combined with a gallium scan 
and chest x-ray 
Lyme Disease Lyme Titer  
 
There are other differential diagnoses that should be considered for CMVR, other than 
infectious causes. Leukemia retinal lesions can have a very similar appearance to the 
lesions seen in CMVR.  In this case the lesions are white-centered hemorrhages and 
cotton wool spots.  Other changes you might see with leukemia infiltration of the retina 
include vitreo-retinal neovascularization, vein occlusion, vitreous and choroidal 
hemorrhage.  Optic neuropathy can also be seen.  Biopsy of the ocular tissues involved is 
considered diagnostic (17).  
 
Vascular occlusions should also be considered as the appearance of large hemorrhages 
with adjacent retinal exudates can look very similar to the lesion seen in CMVR (Figure 
4). The most common cause of vascular occlusion is systemic hypertension and the other 
systemic vascular disease.  In office measurement of blood pressure and sugar are useful 
to screen for hypertension and diabetes. Medical laboratory blood testing including CBC 
with differential, cholesterol panels, and HbA1c can all help to elicit the underlying cause 
of a retinal vein occlusion (8).   
 
FIGURE 4: Branch Retinal Vein Occlusion 
 
Source: Pacific University College of Optometry 
 
 
Other Ocular Signs of HIV 
 
There are other signs of HIV that can manifest in the eye other than CMV and the 
previously mentioned secondary opportunistic infections.  One of the most common signs 
of HIV is microvascular changes in the retina known as “HIV retinopathy.” Multiple 
cotton wool spots and retinal hemorrhages can be seen throughout the posterior pole. 
 
Another potential ocular sign of HIV infection is the presence of skin, eyelid or 
conjunctival lesions called Kaposi Sarcoma (KS).  KS has been linked to infection with a 
virus in the herpes family (HHV-8).  This virus is thought to encourage the growth of 
abnormal cells (Figure 5) (18). KS is generally found in AIDS patients with associated 
lower CD4 counts. 
 
Figure 5: Kaposi’s Sarcoma on Eyelid 
 Source: http://www.pacificu.edu/optometry/ce/courses/32428/32428-1.cfm 
 
Other opportunistic infections can target the anterior segment including herpes simplex 
and zoster.  Molluscum contagiosium lesions can also occur due to a poxvirus (Figure 6). 
 
Figure 6: Molluscum contagiosium lesion 
 
Source: http://en.wikipedia.org/wiki/File:Molluscaklein.jpg (Image licensed from Evanherk from nl under a 
Creative Commons Attribution-Share Alike 3.0 Unported license).   
 
 
Conclusion 
 
Cytologmegalovirus retinitis (CMVR) is a condition affecting primarily HIV/ AIDS 
infected individuals.  CMVR is the leading cause of blindness within this population.  
With the advent of modern HIV treatment, CMVR rates have been dramatically reduced.  
Still AIDS and HIV are not gone, and almost 1 in 5 patients are not aware they are 
infected with this devastating disease.  The public health implications of detecting 
CMVR, as well as the impact on the individual patient are quite serious. In this case, 
medical laboratory testing was the key to the final diagnosis.   
 
The patient above is also a hallmark example of the importance of routine dilation of all 
new patients.   Not all patients who appear healthy are in-fact healthy.  
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